CCL Industries enters its May 13 Q1 results with a mildly softer tape and a cluster of executive share sales that deserves attention ahead of the print.
The insider picture is the most notable angle this week. In early March, the CEO, CFO, a Senior VP, a divisional President, and General Counsel all sold stock on the same day — a coordinated sell-on-award pattern, where awards and disposals were filed simultaneously. The CEO, Geoffrey Martin, sold 16,005 shares near CAD 91.50, realising roughly USD $1.07 million. The CFO and Senior VP each cleared close to USD $1 million. A later sale by a divisional president at CAD 88.00 on March 26 rounded out the activity. The 90-day net across all transactions is a positive USD $6.7 million in value sold, and while award-linked selling is routine, the breadth — covering virtually every C-suite level — is worth noting with the stock now trading below those sale prices at CAD $85.91.
The short-interest setup adds a modest layer. Positioning is light overall at 0.74% of the free float, but it moved in an interesting direction over the past week. Short interest climbed roughly 10% week-on-week, reversing a sharp drop from earlier in April when positions fell from around 1.2% of float (mid-March levels) to below 0.75%. The borrow market, however, tells a calmer story: cost to borrow has collapsed to just 0.63% annually, down two-thirds over the week after hitting intraday spikes above 2% through mid-April. Availability remains extremely loose — the 52-week high on utilization was just 2.28%, and the current reading is a fraction of that — so there is ample capacity for shorts to add without any squeeze pressure at all. The ORTEX short score of 31 is consistent with a stock that is modestly monitored but not under meaningful bearish pressure.
The Street leans constructive. The consensus is a buy, with four outperform-rated analysts on the name and no recent rating changes in the data. Valuation multiples are gradually compressing: the PE has drifted down to 17x over the past month, the EV/EBITDA to 9.5x, and the price-to-book to 2.5x — all modest moves lower, reflecting the stock's 0.6% decline over the past month to CAD 85.91. The forward earnings yield factor scores in the 61st percentile on an EV/EBIT basis, and the 12-month forward EPS growth estimate ranks in the 78th percentile — suggesting the Street still prices in meaningful earnings growth even as multiples quietly drift lower. The dividend score ranks in the 100th percentile, a reflection of a consistent payout history, though the dividend data in the feed predates 2023 and should be verified independently.
The institutional register is dominated by a single anchor: 1281228 Ontario Inc. holds 14.4% of shares with no change reported as of late March. FMR (Fidelity) added 1.22 million shares through February, BlackRock added 288,000 through March, and Cardinal Capital added 340,000 — a string of incremental buys from active managers against a backdrop where the founding family entity has not moved. The breadth of small additions across RBC, BMO, Dimensional, Mackenzie, and Invesco suggests continued institutional confidence at current levels.
On earnings history, the last print in February delivered a +6.6% one-day gain, while the November 2025 event was essentially flat at +0.4%. The stock has not posted a large downside reaction in the two most recent quarters. Close peers had a tougher week: AMCR fell 6.2%, SLGN dropped 4.8%, and GEF slid 3.5%, all underperforming CCL.B's relatively contained 0.8% decline. That relative resilience, against sector headwinds, is a data point the bulls will highlight.
The Q1 print on May 13 is the next focal point. With executive selling clustered at prices above current levels, shorts quietly adding over the past week, and multiples drifting lower, the question for the release is whether the 78th-percentile forward earnings growth expectation is confirmed or revised.
See the live data behind this article on ORTEX.
Open CCL.B on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
